BioVaxys Receives License For Cancer Immunotherapy.
July 11, 2018
The New York Business Journal (7/10, George) reports biotechnology company BioVaxys “has entered into an exclusive, worldwide license agreement with Thomas Jefferson University for a immunotherapy technology developed to potentially treat ovarian cancer,...